Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostate cancer susceptibility candidate protein 1 (PRAC1) is a small nuclear protein of approximately 6 kDa, encoded by the PRAC1 gene on chromosome 17q21, located about 4 kb downstream from the HOXB13 gene. It is specifically and highly expressed in prostate, rectum, and distal colon tissues, as well as in some prostate cancer cell lines. Protein localization studies and sequence analysis suggest a regulatory function in the nucleus, potentially related to tissue-specific gene expression. Aberrant epigenetic regulation (notably DNA methylation) of PRAC1 is associated with more aggressive tumor behavior and poor prognostic features in both prostate and bladder cancers, indicating utility as a prognostic biomarker; however, it is not currently considered a therapeutic target, and no known drugs interact directly with PRAC1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostate cancer susceptibility candidate protein 1 (PRAC1).